XSHE
002584
Market cap783mUSD
Oct 09, Last price
8.75CNY
1D
-2.34%
1Q
-0.11%
IPO
62.72%
Name
Xilong Scientific Co Ltd
Chart & performance
P/E
—
P/S
0.70
EPS
—
Div yield, %
0.22%
Shrs. gr., 5y
1.67%
Rev. gr., 5y
6.38%
Revenues
7.33b
-6.21%
Net income
-75m
L
CFO
69m
-77.04%
Dividend
Dec 23, 20240.033 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Xilong Scientific Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and distribution of chemical reagents. Its comprehensive product portfolio encompasses a wide array of specialized chemicals, including general chemical reagents, high-purity reagents, and those specifically for Printed Circuit Boards (PCB). Furthermore, the company supplies food additives, active pharmaceutical and chemical materials, and various lab glassware products. Beyond its domestic operations in China, Xilong Scientific also extends its market reach through product exports. Established in 1983 and headquartered in Shantou, China, the company underwent a name change in December 2015, transitioning from its former identity as Xilong Chemical Co., Ltd.
Key people
Shaoqun Huang
Chairman of the Board · since 2024
Ye Zhao
President, Director · since 2024
Li Zhang
Chief Financial Officer · since 2024
Zhenjie Huang
Vice President, Director
Hongbo Qi
Vice President · since 2024
Yan Zong
Vice President, Secretary of the Board
Weibo Huang
Director · since 2013
Weipeng Huang
Director · since 2013
Zhenkai Huang
Vice Chairman of the Board, Vice President · since 2013
Xiaoxuan Liu
Independent Director
Shoufu Wu
Independent Director
Independent Director
Headquarters & legal address
汕头市潮汕路西陇中街1-3号
汕头市, GD 100000
CN
汕头市, GD 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||